Onesource Specialty Pharma reported a strong Q2 FY27 performance with 37% year-on-year revenue growth, crossing INR 5 billion. EBITDA margins expanded to 32% as the company benefited from significant operating leverage. Management has successfully commissioned a new 500-liter sterile production line and reaffirmed its FY28 guidance of $400 million in revenue and $160 million in EBITDA, signaling confidence in sustained long-term growth.
Onesource Specialty Pharma Q2 Profitability and Capacity Surge
Revenue grew 37% year-on-year, crossing INR 5 billion for the quarter.
EBITDA surged 53% year-on-year with margins expanding to 32%.
Reader Takeaway: Strong operational leverage and new capacity drive growth; monitor shipping-related working capital impacts in coming quarters.
What just happened
Onesource Specialty Pharma delivered a robust performance in Q2 FY27, characterized by significant margin expansion and volume growth in its core injectables and DDC segments. EBITDA growth of 53% outpaced revenue growth of 37%, reflecting high operating efficiency. The company officially brought a new 500-liter sterile batch line online in September, effectively doubling its production capacity to meet rising demand.
Why this matters
The successful operationalization of the new DDC line is a critical milestone for scaling revenue. Furthermore, the company has completed Factory Acceptance Testing for a third production line, which is currently undergoing site qualification. Management’s decision to reaffirm its FY28 target of $400 million revenue and $160 million EBITDA provides long-term earnings visibility for investors.
Management Commentary
Management attributed a recent increase in trade receivables to temporary global shipping bottlenecks, which have extended cycle times by 45 to 60 days, rather than structural issues. They confirmed that the effective tax rate will remain at current levels through Q3 FY28 due to the carry-forward of previous tax losses. Additionally, the company highlighted new project wins in the biologics segment and the launch of generic semaglutide in Saudi Arabia via partner Hikma.
Risks to watch
Investors should monitor the qualification timeline for the third production line, as bespoke pharmaceutical manufacturing equipment is prone to potential commissioning delays. Additionally, while management describes current working capital fluctuations as temporary, ongoing geopolitical tensions and global supply chain disruptions remain an external risk factor affecting shipping cycle times.
What to track next
Key focus areas include the speed of utilization ramp-up for the new 500-liter sterile line and the official commercialization of the third line, currently targeted for Q4 FY28. Future long-term growth will likely hinge on the commercial revenue contribution from the biologics segment, expected to ramp up in FY29.